Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells $15,572.02 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) CFO Jason O’byrne sold 1,634 shares of Vir Biotechnology stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $9.53, for a total transaction of $15,572.02. Following the sale, the chief financial officer owned 162,615 shares in the company, valued at $1,549,720.95. This represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Jason O’byrne also recently made the following trade(s):

• On Monday, February 23rd, Jason O’byrne sold 2,089 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.45, for a total transaction of $15,563.05.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $9.09 on Friday. The stock’s 50-day moving average is $7.01 and its two-hundred day moving average is $6.08. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of -2.88 and a beta of 1.69. Vir Biotechnology, Inc. has a 1 year low of $4.16 and a 1 year high of $10.94.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.11. The business had revenue of $64.07 million during the quarter, compared to the consensus estimate of $19.91 million. Vir Biotechnology had a negative return on equity of 49.31% and a negative net margin of 638.88%.The business’s quarterly revenue was up 417.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.76) EPS. As a group, research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current year.

Institutional Investors Weigh In On Vir Biotechnology

Several hedge funds have recently modified their holdings of VIR. ARCH Venture Management LLC purchased a new position in Vir Biotechnology in the 2nd quarter valued at $65,100,000. GSK plc purchased a new position in Vir Biotechnology during the 4th quarter worth $51,562,000. State Street Corp lifted its stake in shares of Vir Biotechnology by 18.9% in the 4th quarter. State Street Corp now owns 6,229,555 shares of the company’s stock worth $37,564,000 after acquiring an additional 988,262 shares during the period. Orbimed Advisors LLC boosted its holdings in shares of Vir Biotechnology by 5.9% in the second quarter. Orbimed Advisors LLC now owns 2,380,715 shares of the company’s stock valued at $11,999,000 after acquiring an additional 132,466 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Vir Biotechnology by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 2,328,207 shares of the company’s stock worth $14,041,000 after acquiring an additional 81,985 shares during the period. 65.32% of the stock is owned by institutional investors and hedge funds.

Vir Biotechnology News Summary

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas agreed to a collaboration on Vir’s prostate‑cancer asset (VIR‑5500) that includes up‑front and potential milestone payments totaling up to ~$1.7B, materially de‑risking that program and improving commercialization prospects. Read More.
• Positive Sentiment: Q4 results surprised to the upside: EPS and roughly $64M revenue beat consensus, signaling stronger commercial traction and likely underpinning recent analyst optimism. Read More.
• Positive Sentiment: Analysts have raised targets and ratings following the results and deal flow (Needham moved its target to $18), supporting upside from fundamentals despite volatility. Read More.
• Neutral Sentiment: Management will present at TD Cowen and Leerink in early March — useful for additional color and Q&A but not an immediate earnings/cash catalyst. Read More.
• Neutral Sentiment: Increased media/peer comparisons (head‑to‑head coverage) have raised visibility and trading volume; this can amplify moves but doesn’t change Vir’s underlying cashflow or pipeline. Read More.
• Negative Sentiment: Vir priced an underwritten offering of 17,647,058 shares at $8.50 (~$150M gross), which strengthens the balance sheet but is dilutive and increased near‑term share supply — a clear short‑term negative for the stock. Read More.
• Negative Sentiment: Market coverage singled out the discounted offering as the proximate cause of the post‑rally pullback, triggering selling and higher volatility. Read More.
• Negative Sentiment: Multiple insider sales were disclosed last week (including CEO and other senior officers/directors), increasing visible supply and feeding negative sentiment alongside the offering. Individual filings and summaries are available in SEC/insider reports. Read More.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a report on Tuesday, December 30th. Wall Street Zen upgraded shares of Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday. Leerink Partners reiterated an “outperform” rating and set a $20.00 price target on shares of Vir Biotechnology in a research note on Thursday. Needham & Company LLC raised their price objective on shares of Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Finally, Morgan Stanley upped their target price on shares of Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vir Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $19.89.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.